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Background: Statins are used to treat hypercholesterolemia in patients with type 2 diabetes mellitus, but many of
these patients fail to achieve the target LDL-C level. Recent reports have suggested that a synergistic effect can be
obtained by concomitant administration of the cholesterol absorption inhibitor ezetimibe and a statin. However, in
patients with type 2 diabetes who are already being treated with satins, it remains unclear whether it is more
effective to add ezetimibe or to increase the statin dose. Therefore, this study was performed to examine the
effects of these two regimens on LDL-C and lipoproteins.
Methods: The subjects were type 2 diabetic patients under treatment with rosuvastatin (2.5 mg daily), who had
LDL-C levels ≥80 mg/dL. They were randomly allocated to a group that received add-on therapy with ezetimibe at
10 mg/day (combination group, n = 40) or an increase of the rosuvastatin dose to 5 mg/day (dose escalation
group, n = 39). These two groups were compared at baseline and after 12 weeks of treatment.
Results: The percent change of LDL-C was −31% in the combination group and −12% in the dose escalation
group. Both groups showed a significant decrease, but the decrease was greater in the combination group. In both
groups, there was a significant decrease in the levels of small dense LDL-C, oxidized LDL and remnant-like
lipoprotein cholesterol. For all of these parameters, the percent changes were greater in the combination group.
Only the combination group showed a significant decrease of triglycerides. Multivariate analysis was performed to
identify factors associated with reaching an LDL-C level <80 mg/dL. As a result, add-on therapy with ezetimibe was
extracted as a factor related to improvement of LDL-C.
Conclusions: Compared with increasing the dose of rosuvastatin, the combination of rosuvastatin and ezetimibe
not only achieves quantitative but also qualitative improvement of serum lipid levels in type 2 diabetic patients,
suggesting that this combination could suppress the progression of atherosclerosis.
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Type 2 diabetes mellitus is an important risk factor for
atherosclerotic diseases. A meta-analysis has shown that
the risk of developing coronary artery disease and stroke
increased by 2.0-fold and 2.3-fold, respectively, in pa-
tients with diabetes mellitus [1]. A recent report on the
Japan Diabetes Complications Study (JDCS), which is
being conducted in patients with type 2 diabetes, showed
that both LDL-C and TG are risk factors for cardiovas-
cular events [2], and improvement of dyslipidemia in
patients with diabetes is believed to contribute greatly to
preventing the development of atherosclerosis.
Characteristics of lipid metabolism in patients with
diabetes include susceptibility to development of hyper-
LDL-cholesterolemia, hypertriglyceridemia, and hypo-
HDL-cholesterolemia, in addition to quantitative and
qualitative abnormalities of lipoproteins, such as an in-
crease of small dense LDL-cholesterol (sdLDL-C), oxi-
dized cholesterol (oxidized low-density lipoprotein
cholesterol; oxidized LDL), and remnant lipoprotein [3].
Although many patients with type 2 diabetes currently
receive treatment based around statins, the achievement
rate of the target LDL-C level remains low with statin
therapy alone [4].
Ezetimibe inhibits Niemann-Pick C1-like protein 1
(NPC1L1), a cholesterol transporter that exists in the
small intestinal mucosa, and reduces serum cholesterol
by suppressing the absorption of dietary and biliary chol-
esterol from the small bowel [5]. In recent years, con-
comitant use of statins and ezetimibe has been reported
to have a greater LDL-lowering effect [6]. For example,
the SHARP study showed that LDL-C-lowering therapy
using the combination of ezetimibe and a statin led to a
decrease of atherosclerotic events [7]. However, only a
few studies have directly compared whether it is better
to increase the statin dose or to add ezetimibe to basal
statin therapy in hypercholesterolemic patients with type
2 diabetes who have not shown a sufficient response to
statin monotherapy.
The present study investigated hypercholesterolemic
patients with type 2 diabetes on rosuvastatin at 2.5 mg/day,
whose levels of LDL-C levels were higher than 80 mg/dL
despite this treatment. These patients were randomly allo-
cated to a group that received a higher dose of rosuvastatin
(5 mg/day) or a group that received add-on therapy with
ezetimibe at 10 mg/day. The effects on LDL-C and on
qualitative improvement of atherosclerosis-inducing lipo-
proteins were compared after 12 weeks of administration.
Methods
Subjects
The subjects of this study (UMIN000011005) were
hypercholesterolemic patients with type 2 diabetes aged
from 20 years to less than 80 years, who had beenreceiving rosuvastatin (2.5 mg/day) for more than
12 weeks but had LDL-C levels higher than 80 mg/dL,
whose therapeutic regimen had not been changed for
the past three months, and who had an HbA1c (NGSP)
of less than 8.4%. In the JAPAN-ACS Study [8] and the
COSMOS Study [9], progression of coronary plaque was
significantly prevented by reducing the LDL-C level to
75 mg/dL and 80 mg/dL, respectively. Also in the JART
Study [10], progression of coronary plaque was significantly
suppressed in the consolidation therapy group (mean
LDL-C level: 83.7 mg/dL) compared with the standard
therapy group (mean LDL-C level: 117.4 mg/dl). In a co-
hort study of Japanese diabetic patients without a history
of cardiovascular disease, the incidence of cardiovascular
events was higher among the patients with LDL-C levels
above 80 mg/dL [11]. Based on these reports, we selected
diabetic patients with LDL-C levels higher than 80 mg/dL
for the present study. Patients with a history of familial
hypercholesterolemia, patients who had developed stroke
or ischemic heart disease within the past six months,
patients with liver failure (ALT and/or AST >80 IU/L)
or kidney failure (serum creatinine >1.3 mg/dL), patients
using insulin, patients who were pregnant or could pos-
sibly become pregnant, and patients who were breast
feeding were excluded from the study. All patients were
Japanese. This study was conducted with the approval of
the Ethics Committee of the University of Occupational
and Environmental Health, Japan, and written consent to
the study was obtained from all subjects.
Study protocol
The study employed a randomized open-label design.
Patients with type 2 diabetes on treatment with
rosuvastatin at 2.5 mg/day (n = 79) were randomly allo-
cated to two groups by the envelope method: the add-on
ezetimibe group (combination group) that received
2.5 mg/day of rosuvastatin and 10 mg/day of ezetimibe
(n = 40), and the rosuvastatin dose escalation group that
received 5 mg/day of rosuvastatin (n = 39). During the
study period, patients were prohibited from receiving
new drugs or discontinuing drugs, changing the dosage
and administration, or undergoing new lifestyle modifi-
cation including exercise therapy and diet therapy. Evalu-
ation was performed at the beginning of the study and
12 weeks after initiation of the study by fasting blood tests.
The study endpoints were serum lipids, including LDL-C,
HDL-C, sdLDL-C, oxidized LDL (malondialdehyde-
modified low-density lipoprotein; MDA-LDL), TG, and
remnant-like particle cholesterol (RLP-C), as well as other
clinical tests such as fasting blood glucose, HbA1c, fasting
serum insulin, and high sensitivity C-reactive protein.
These were measured at baseline and after 12 weeks.
The primary endpoint was set as the percent change of
LDL-C after 12 weeks compared with baseline. Secondary
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oxidized LDL (MDA-LDL), TG, and RLP-C after 12 weeks
compared with baseline.
Laboratory tests
Venous blood sampling was performed early in the morn-
ing after fasting for over 12 hours. Serum lipids were mea-
sured using the Hitachi 7350 autoanalyzer (Hitachi Co.,
Tokyo, Japan). LDL-C, HDL-C, and TG were measured by
enzymatic methods, and LDL-C was measured by the
direct method. sdLDL-C was measured using the sdLDL-
EX reagent “SEIKEN” (Denka Seiken Inc., Tokyo, Japan)
and a Hitachi 7170 autoanalyzer (Hitachi Co., Tokyo, Japan)
by the homogeneous assay [12]. MDA-LDL was measured
by a sandwich ELISA method using the oxidative ELISA
“Daiichi” (Sekisui Medical, Tokyo, Japan). RLP-C was mea-
sured using the RLP-C reagent “JIRO-II” (Otsuka Inc.,
Tokyo, Japan) and the Hitachi 7170 autoanalyzer (Hitachi
Co., Tokyo, Japan). The insulin resistance index (HOMA-
IR) was calculated by the following formula: fasting IRI
(mU/L) × fasting blood glucose (mg/dL)/405. HbA1c (%)
was measured by HLPC with a Tosoh HLC-723 G8 (Tosoh
Co., Kyoto, Japan), and results were expressed as National
Glycohemoglobin Standardization Program (NGSP) values
by adding 0.4% to the conventional Japanese standard
substance (JDS) HbA1c values (JDS values) [13].
Statistical analysis
Results are expressed as the mean ± standard deviation.
Assuming that the LDL-C lowering effect was 21% when
rosuvastatin and ezetimibe were used concomitantly, and
6% when the rosuvastatin dose was doubled [14], the num-
ber of subjects required was calculated to be 32 patients
per group according to the t-test (two-tailed hypothesis)
with the significance level α and power 1-β set as 5% and
90%, respectively. Assuming a dropout rate of 20%, the
target sample size of 80 patients was established. Normality
of data distributions was assessed using the Shapiro-Wilk
test. Comparison of baseline data and 12-week data was
performed using the paired t-test if a normal distribution
was found, or the Wilcoxon signed rank test was used
when the distribution was not normal. Comparison of
percent changes between the two groups was performed
using Student’s t-test if a normal distribution was found, or
the Mann–Whitney U-test was used if the distribution was
not normal. For categorical data, Fisher’s exact probability
test was employed when the expected cell size was less
than 5, while the chi-square test was used otherwise.
Univariate and multivariate logistic regression analyses were
performed by classifying patients with LDL-C <80 mg/dL
at Week 12 as the improved group, and others as the unim-
proved group. The odds ratio and 95% confidence interval
are shown for all data. Multivariate logistic regression ana-
lysis was performed using step-up procedures with factorsshowing p < 0.25 in univariate logistic regression analysis,
from which factors showing multicollinearity based on
the Spearmann’s rank correlation analysis were removed.
Analyses were performed using SPSS Statistical Software
21.0 (SPSS Inc., Chicago, IL), and P < 0.05 was considered
significant.
Results
Baseline clinical characteristics of the subjects
The subjects were 79 patients (men, 41; women, 38),
including 40 patients in the add-on ezetimibe group (com-
bination group) that received 2.5 mg/day of rosuvastatin
and 10 mg/day of ezetimibe, and 39 patients in the
increased rosuvastatin dose group (dose escalation group)
that received 5 mg/day of rosuvastatin. Of these, one
patient in the combination group and three patients in the
dose escalation group dropped out due to discontinued
hospital attendance. Consequently, analysis was performed
on 39 patients in the combination group and 36 patients in
the dose escalation group. Age, sex, body mass index
(BMI), systolic blood pressure, diastolic blood pressure,
waist circumference, and the presence of metabolic syn-
drome (MetSyn) were comparable between the combin-
ation and dose escalation groups (Table 1).
Effect on clinical parameters
Serum lipids at Week 0 and Week 12 in both groups are
shown in Table 2. Percent changes from Week 0 are
shown in Figure 1.
The LDL-C level, which was the primary endpoint,
showed a significant decrease after 12 weeks relative to
baseline in both groups. The combination group reduced
the serum concentration of LDL-C from 111 ± 26 mg/dL
to 75 ± 18 mg/dL (p < 0.001) and the dose escalation group
from 112 ± 22 mg/dL to 98 ± 22 mg/dL (p < 0.001). Com-
parison between the two groups revealed that the percent
change of LDL-C was −31% in the combination group
and −12% in the dose escalation group, showing a signifi-
cant decrease in the combination group (p < 0.001). While
the LDL-C level <100 mg/dL increased from 31% to 58%
in the dose escalation group, it increased from 44% to 90%
in the combination group, and the increase was signifi-
cantly greater in the combination group (p = 0.002). In
addition, the rate of achieving an LDL-C level <80 mg/dL
increased from 0% to 22% in the dose escalation group
and from 0% to 62% with ezetimibe therapy, and the
combination group showed significantly greater improve-
ment (p = 0.001). The factors influencing improvement
of LDL-C were examined by classifying patients with an
LDL-C level <80 mg/dl in Week 12 as the improved
group and others as the unimproved group (Table 3). As
a result of multivariate logistic regression analysis, the
treatment and the LDL-C level in Week 0 were extracted
as factors affecting improvement of LDL-C: the chance of






Age, years 66.3 ± 11.7 63.0 ± 13.0 0.210
Male gender, n (%) 24 (62) 16 (44) 0.138
BMI, kg/m2 25.1 ± 3.6 26.5 ± 4.5 0.143
Systolic blood pressure, mmHg 127.4 ± 14.9 126.7 ± 13.8 0.849
Diastolic blood pressure, mmHg 72.2 ± 10.8 72.9 ± 8.0 0.754
Waist circumference, cm 90.5 ± 11.8 93.1 ± 11.0 0.360
MetSyn, (%) 17 (50) 18 (58) 0.515
Prevalence CVD, n (%) 4 (10) 2 (6) 0.376
Prevalence CI, n (%) 4 (10) 4 (11) 0.598
Hypertension, n (%) 28 (72) 23 (64) 0.463
Diabetes therapy
Oral hypoglycemic agent, n (%) 30 (77) 30 (83) 0.488
sulfonylurea, n (%) 16 (41) 19 (53) 0.143
pioglitazone, n (%) 17 (44) 15 (42) 0.866
metformin, n (%) 14 (36) 15 (42) 0.608
α-glucosidase inhibitor, n (%) 8 (21) 3 (12) 0.136
dipeptidyl peptidase-4 inhibitor, n (%) 3 (8) 4 (11) 0.454
Aspartate aminotransferase, U/L 27.2 ± 12.5 21.9 ± 5.6 0.596
Alanine aminotranserase, U/L 28.2 ± 16.3 21.2 ± 9.8 0.216
Creatine kinase, IU/L 130 ± 87 118 ± 63 0.489
Creatinine, mg/dL 0.8 ± 0.3 0.7 ± 0.2 0.316
Data are mean ± SD, n, or n (%). Rosuva Rosuvastatin, Eze Ezetimibe, BMI Body mass index, MetSyn Metabolic syndrome [diagnosed by the criteria in japan],
CVD Cardiovascular disease, CI Cerebral infarction.
P values are for differences between two groups at baseline.
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for patients from the combination group compared with
the dose escalation group (95% CI 1.89-20.91), and it in-
creased by 0.95-fold as LDL-C in Week 0 increased by
1 mg/dL (95% CI 0.92-0.98).
sdLDL-C levels decreased significantly after 12 weeks
relative to baseline in both groups. The percent change of
sdLDL-C was −31% in the combination group and −14%
in the dose escalation group, showing a significant de-
crease (p = 0.008) in the combination group.
MDA-LDL levels decreased significantly after 12 weeks
relative to baseline in both groups. The percent change
of MDA-LDL was −22% in the combination group
and −11% in the dose escalation group, showing a sig-
nificant decrease (p = 0.049) in the combination group.
HDL-C showed no significant change in both groups.
TG levels only decreased significantly in the combin-
ation group. The percent change of TG was −14% in the
combination group and −1% in the dose escalation
group, showing a significant decrease (p = 0.032) in the
combination group.
RLP-C levels decreased significantly after 12 weeks
relative to baseline in both groups. The percent changeof RLP-C was −28% in the combination group and −13%
in the dose escalation group, showing a significant
decrease (p = 0.014) in the combination group.
Fasting blood glucose, fasting IRI, HOMA-IR, and
HbA1c showed no significant differences between Week
0 and Week 12 in both groups (Table 4).
Both groups exhibited no significant increases of CK
or ALT and AST (data not shown), confirming good
tolerability.
Discussion
In this study, combination therapy with ezetimibe had a
stronger LDL-C lowering effect than an increased dose
of rosuvastatin in patients with type 2 diabetes who
maintained LDL-C levels higher than 80 mg/dL despite
treatment with 2.5 mg/day of rosuvastatin. In addition,
combination therapy led to further improvement of
sdLDL-C, MDA-LDL, TG, and RLP-C, suggesting that
the qualitative improvement of highly atherogenic lipo-
proteins was also greater.
Statins inhibit cholesterol synthesis in the liver, but this
result in enhanced cholesterol absorption and that de-
creases the cholesterol-lowering effect [15]. Thus, addition
Table 2 Serum lipid parameters and Patients achieving




Baseline 12 weeks *P value
LDL-C, mg/dL
Rosuva/Eze 2.5/10 mg 111 ± 26 75 ± 18 < 0.001
Rosuva 5 mg 112 ± 22 98 ± 22 < 0.001
sdLDL-C, mg/dL
Rosuva/Eze 2.5/10 mg 34 ± 11 22 ± 7 < 0.001
Rosuva 5 mg 34 ± 11 28 ± 11 0.001
MDA-LDL, U/L
Rosuva/Eze 2.5/10 mg 112 ± 29 86 ± 22 < 0.001
Rosuva 5 mg 117 ± 34 100 ± 30 0.003
HDL-C, mg/dL
Rosuva/Eze 2.5/10 mg 57 ± 16 57 ± 16 0.861
Rosuva 5 mg 56 ± 11 58 ± 13 0.185
LDL/HDL ratio
Rosuva/Eze 2.5/10 mg 2.1 ± 0.8 1.4 ± 0.4 < 0.001
Rosuva 5 mg 2.0 ± 0.5 1.8 ± 0.5 < 0.001
TG, mg/dL
Rosuva/Eze 2.5/10 mg 147 ± 71 118 ± 56 0.001
Rosuva 5 mg 147 ± 79 136 ± 68 0.700
RLP-C, mg/dL
Rosuva/Eze 2.5/10 mg 4.9 ± 2.9 3.0 ± 1.1 < 0.001





LDL-C < 80, n (%)
Rosuva/Eze 2.5/10 mg 0 (0) 24 (61.5)†
Rosuva 5 mg 0 (0) 8 (22.2)
Patients achieving
LDL-C < 100, n (%)
Rosuva/Eze 2.5/10 mg 17 (43.6) 35 (89.7)†
Rosuva 5 mg 11 (30.6) 21 (58.3)
Data are mean ± SD, n (%). Rosuva Rosuvastatin, Eze Ezetimibe, LDL
Low-density lipoprotein cholesterol, sdLDL-C Small dense low-density
lipoprotein cholesterol, MDA-LDL Malondialdehyde-modified low-density
lipoprotein, sdLDL-C Small dense low-density lipoprotein cholesterol, HDL-C
High-density lipoprotein cholesterol, TG Triglycerides, RLP-C Remnant-like
particle cholesterol.
There were no significant differences among each baseline values.
*P values are for differences between baseline with 12 week.
†P <0.01 for determine the association between-treatment difference,
the Fisher’s exact test was used.
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complementary action to statins, had a greater LDL-C-
lowering effect. In addition, the percent reduction of
LDL-C was −31% in the group that received ezetimibe,
which was equal to the previously reported range in
patients with dyslipidemia [6,14]. Vaverkova et al. andGianluca et al. [16,17] reported that, similar to the
results of the present study, the reduction of LDL-C
with combined use of ezetimibe was higher among
patients with type 2 diabetes compared to those with
normal glucose tolerance. Cholesterol absorption from the
small intestine is facilitated by the NPC1L1 transporter. In
patients with diabetes, expression of NPC1L1 is enhanced
[18], whereas there is reduced expression of ATP-binding
cassette transporters (ABC) G5 and G8, which are in-
volved in returning cholesterol from small intestinal
epithelial cells to the small bowel lumen [19]. Accord-
ingly, patients with diabetes exhibit increased cholesterol
absorption. Based on this background, it is considered
likely that combination therapy with ezetimibe will have
a more powerful effect in hypercholesterolemic patients
with diabetes whose cholesterol absorption is enhanced,
given that ezetimibe selectively inhibits cholesterol ab-
sorption from the intestine by binding to the NPC1L1
receptor.
In recent years, it has become clear that a decrease in
the size of LDL particles is associated with the risk of
coronary artery disease, and people who mainly have
sdLDL-C, as opposed to those with normal-sized LDL,
are known to show a three-fold higher incidence of
CHD [20]. On the other hand, it has been reported that
patients with type 2 diabetes often have sdLDL-C [21],
suggesting that not only maintaining a low blood level
of LDL-C but also an increase in the size of LDL parti-
cles are essential for the prevention of atherosclerosis.
In a previous study, ezetimibe combination therapy and
statin monotherapy reportedly showed similar sdLDL-C-
lowering effects [22]. However, there has been no report
about patients with type 2 diabetes mellitus who were
already receiving statin therapy, and this is the first study
to show that ezetimibe combination therapy has a greater
sdLDL-C-improving effect than statin monotherapy in
patients already using statins.
Oxidized LDL, including MDA-LDL, is a marker of
oxidative stress, and has been reported to serve as a
predictor of cardiovascular events [23]. Oxidized LDL is
closely related to progression of atherosclerosis, includ-
ing the formation of foam cells, vascular endothelial
dysfunction, and vascular inflammation [24]. In coronary
artery disease, diabetes mellitus, and metabolic syn-
drome, the level of oxidized LDL has been reported to
be high [25], and it is thought to be closely involved in
the pathology of diabetes as well as the progression of
vascular complications. Regarding changes of MDA-LDL,
only a few reports have compared statin monotherapy
with ezetimibe combination therapy, and none of the
previous studies targeted only patients with diabetes
mellitus. In the present study, ezetimibe combination
therapy showed a greater MDA-LDL-lowering effect
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Figure 1 Percent changes from baseline of Serum lipids. Mean percent change from baseline (mean [SD]) of low-density lipoprotein
cholesterol (LDL-C) (A), small dense low-density lipoprotein cholesterol (sdLDL-C) (B), malondialdehyde-modified low-density lipoprotein
(MDA-LDL) (C), high-density lipoprotein cholesterol (HDL-C) (D), triglycerides (TG) (E), and remnant-like particle cholesterol (RLP-C) (F) after
12 weeks of treatment. R/E 2.5/10 mg indicates rosuvastatin 2.5 mg + add-on ezetimibe 10 mg; R 5 mg indicates rosuvastatin 5 mg. Open
columns indicate R/E 2.5/10 mg; filled columns indicate R 5 mg. Values are the means ± SD. Data were compared by Student’s t-test for normally
distributed variables and the Mann–Whitney U test for variables with a skewed distribution.
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tients with impaired glucose tolerance and coronary ar-
tery disease. The effectiveness of this combination
therapy in patients with diabetes mellitus was thus
emphasized.
Remnant lipoproteins accumulate in the vessel wall,
and are involved in the onset and progression of athero-
sclerosis, such as foam cell formation, vascular endothe-
lial dysfunction, promotion of vascular smooth muscle
proliferation, and production of PAI-1 [27]. Remnant
lipoprotein levels rise from the stage of abnormal glu-
cose tolerance [28], and reportedly increase even without
the presence of obvious dyslipidemia [29]. In other
words, in patients with diabetes mellitus, qualitative ab-
normalities of lipoproteins may be one of the reasons why
the risk of cardiovascular events is so high. Some studies
have compared statin monotherapy and ezetimibe com-
bination therapy in patients with abnormal glucosetolerance and coronary artery disease [26,30], but there
has never been a study only targeting patients with
diabetes mellitus. In the present study, the percent reduc-
tion of TG and atherosclerosis-inducing RLP-C, so-called
“TG-rich lipoprotein”, was significantly higher in the com-
bined group, suggesting that combination therapy with
ezetimibe can be useful for suppressing the onset and pro-
gression of atherosclerosis by controlling remnant lipopro-
teins in diabetic patients.
In the present study, the levels of TG, sdLDL-C, RLP-
C, and MDL-LDL were markedly improved in the group
receiving concomitant treatment with ezetimibe. The
mechanism by which ezetimibe decreases TG levels
remains unclear, although this drug has been suggested
to decrease TG levels by inhibiting cholesterol absorp-
tion, chylomicron production, fatty acid absorption via
FATP4, and apoB-48 production in the small intestine
[31-33]. Regarding the improvement of sdLDL-C and
Table 3 Baseline characteristics associated with achieving LDL-C < 80 mg/dl as analyzed by univariate and multiple
logistic regression analyses
Univariate logistic regression Multiple logistic regression
Wald Χ2 P OR (95% CI) Wald Χ2 P OR (95% CI)
Group, Rosuva/Eze vs. Rosuva 11.0 0.001 5.60 (2.03-15.5) 9.0 0.003 6.29 (1.89-20.91)
Age, per year 0.5 0.461 1.02 (0.97-1.06)
Male gender, male vs. female 3.3 0.068 0.42 (0.16-1.07)
BMI, per kg/m2 0.008 0.930 1.00 (0.89-1.11)
Systolic blood pressure, per mmHg 0.002 0.964 1.00 (0.97-1.03)
Diatolic blood pressure, per mmHg 1.8 0.181 0.97 (0.92-1.02)
Waist circumference, per cm 0.07 0.790 1.01 (0.96-1.05)
MetSyn, yes vs. no 0.001 0.969 0.98 (0.37-2.63)
Prevalence CVD, yes vs. no 0.1 0.706 1.38 (0.26-7.33)
Prevalence CI, yes vs. no 3.3 0.069 4.73 (0.89-25.23)
Hypertension, yes vs. no 0.01 0.904 1.06 (0.40-2.84)
Diabetes therapy
Oral hypoglycemic agent, yes vs. no 1.9 0.169 0.42 (0.12-1.45)
sulfonylurea, yes vs. no 0.05 0.815 1.12 (0.43-2.90)
pioglitazone, yes vs. no 0.1 0.758 0.86 (0.34-2.19)
metformin, yes vs. no 1.6 0.210 1.83 (0.71-4.69)
α-glucosidase inhibitor, yes vs. no 0.7 0.392 1.75 (0.48-6.36)
dipeptidyl peptidase-4 inhibitor, yes vs. no 0.000 0.991 1.01 (0.21-4.86)
LDL-C, per mg/dL 8.2 0.004 0.97 (0.94-0.99) 10.6 0.001 0.95(0.92-0.98)
sdLDL-C, per mg/dL 4.5 0.034 0.95 (0.90-1.00)
MDA-LDL, per U/L 3.3 0.070 0.99 (0.97-1.00)
HDL-C, per mg/dL 3.5 0.061 0.96 (0.93-1.00)
LDL/HDL ratio 0.2 0.677 0.86 (0.43-1.74)
TG, per mg/dL 0.4 0.526 1.00 (0.99-1.00)
RLP-C, per mg/dL 0.2 0.637 0.96 (0.80-1.15)
FPG, per mg/dL 0.07 0.784 1.00 (1.00-1.02)
Fasting serum insulin, per μU/mL 0.009 0.926 1.00 (0.94-1.06)
HOMA-IR 0.004 0.949 1.00 (0.82-1.24)
HOMA-B 0.1 0.739 1.00 (0.99-1.00)
HbA1c, per % 0.3 0.559 1.2 (0.69-2.00)
Aspartate aminotransferase, per U/L 1.6 0.204 1.03 (0.98-1.08)
Alanine aminotranserase, per U/L 3.6 0.058 1.04 (1.00-1.07)
Creatine kinase, per mg/dL 1.03 0.311 1.00 (0.99-1.00)
Creatine, per mg/dL 2.8 0.096 5.7 (0.73-44.58)
Only factors with P < 0.025 on univariate logistic regressions, which were pioglitazone, LDL-C, Alanine aminotranserase, were included in this multiple factor
logistic regression.
Rosuva Rosuvastatin, Eze Ezetimibe, BMI Body mass index, MetSyn Metabolic syndrome [diagnosed by the criteria in japan], CVD Cardiovascular disease, CI Cerebral
infarction, LDL Low-density lipoprotein cholesterol, sdLDL-C Small dense low-density lipoprotein cholesterol, MDA-LDL Malondialdehyde-modified
low-density lipoprotein, HDL-C High-density lipoprotein cholesterol, TG Triglycerides, RLP-C Remnant-like particle cholesterol, FPG Fasting plasma glucose,
HOMA-IR Homeostasis model assessment of insulin resistance, HOMA-B HOMA of β-cell function.
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http://www.lipidworld.com/content/12/1/137RLP-C, ezetimibe is considered to inhibit chylomicron
production and thereby reduce the TG-rich lipoproteins,
which means that this drug decreases the LDL-C level
and normalizes the size of LDL particles [31] and
thereby decreases both sdLDL-C and RLP-C levels.Regarding the improvement of MDA-LDL, ezetimibe
decreases the level of sdLDL-C, which is likely to be
oxidized and degraded [34], and it inhibits the absorp-
tion of dietary oxysterol that is also likely to be oxidized
and degraded [35].
Table 4 Indices of glucose metabolism at baseline and
after 12 weeks of treatment
Baseline 12 weeks P value
FPG, mg/dL
Rosuva/Eze 2.5/10 mg 131 ± 25 135 ± 30 0.278
Rosuva 5 mg 126 ± 21 125 ± 22 0.848
Fasting serum insulin, μU/mL
Rosuva/Eze 2.5/10 mg 8.5 ± 6.9 8.3 ± 6.0 0.435
Rosuva 5 mg 9.1 ± 9.2 9.8 ± 11.0 0.128
HOMA-IR
Rosuva/Eze 2.5/10 mg 2.8 ± 2.4 2.8 ± 2.4 0.983
Rosuva 5 mg 2.7 ± 2.4 3.0 ± 3.0 0.162
HOMA-B
Rosuva/Eze 2.5/10 mg 48 ± 38 45 ± 26 0.412
Rosuva 5 mg 62 ± 94 68 ± 97 0.130
HbA1c,%
Rosuva/Eze 2.5/10 mg 6.7 ± 0.6 6.8 ± 0.7 0.103
Rosuva 5 mg 6.9 ± 0.7 6.9 ± 0.8 0.907
Data are mean ± SD.
Rosuva Rosuvastatin, Eze Ezetimibe, FPG Fasting plasma glucose, HOMA-IR
Homeostasis model assessment of insulin resistance, HOMA-B HOMA of
β-cell function.
There were no significant differences among each baseline values.
P values are for differences between baseline with 12 week.
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http://www.lipidworld.com/content/12/1/137It has been reported that ezetimibe improves insulin
resistance in animals [36] and humans [37]. It has also been
reported that ezetimibe improves insulin resistance in mice
fed a high-fat diet, but not in mice fed a normal diet. This
suggests that ezetimibe may normalize the high-fat diet-
enhanced activity of SREBP-1c and thereby improve
hepatic insulin resistance [38]. Tsunoda et al. reported that
ezetimibe improved insulin resistance in their patients
with high insulin resistance (mean HOMA-IR: 5.3) [37].
In the present study, 44% of the subjects were taking
pioglitazone and 36% were taking metformin before the
start of the study, so their insulin resistance was improved
(mean HOMA-IR:2.8) at the time of the study. Thus, it is
considered that the effect of ezetimibe on insulin resist-
ance might not have been evaluated properly.
This study had the following limitations. The first limita-
tion was a relatively small sample size, and the observation
period was also short. The second limitation is that the
present study used surrogate markers for cardiovascular
events to examine the effectiveness of statin monotherapy
and ezetimibe combination therapy. The results of the cur-
rently ongoing IMPROVE-IT study targeting patients with
acute coronary syndrome will help to determine which of
these therapies can actually prevent atherosclerotic disease.
Conclusions
In hypercholesterolemic patients with type 2 diabetes,
combination therapy with 2.5 mg/day of rosuvastatin and10 mg/day of ezetimibe achieved significantly greater
improvement of not only LDL-C but also sdLDL-C,
MDA-LDL, TG, and RLP-C compared with dose escal-
ation of rosuvastatin monotherapy. In addition, the results
revealed that rather than simply decreasing serum lipids,
combined therapy can also produce qualitative improve-
ment of the lipid profile and shift it toward a more favor-
able profile for the suppression of atherosclerosis. Strong
statins are not sufficiently effective for controlling lipid
levels and attaining the target levels in diabetic patients.
The results of the present study may suggest a useful alter-
native approach when statin therapy fails to control lipid
levels in diabetic patients who are prone to coronary
artery disease.
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